Weight Loss Drugs and Your 2026 Health Insurance Renewal Cycle: Why Employers Need a Cost Containment Strategy Now
GLP-1 (Glucagon-Like Peptide-1) medications such as Ozempic, Wegovy and Mounjaro have transformed obesity and diabetes care. They are clinically effective, increasingly popular, and in many cases genuinely life-changing for patients. But they are also the fastest-growing cost driver in global health insurance programs – and unless employers begin planning now, these medications will continue to put substantial upward pressure on health insurance loss ratios and premiums in 2026.
The intention is not to restrict access. GLP-1s can improve long-term health outcomes, reduce obesity, lower cardiovascular risk and ultimately reduce claims over time. But without a structured, data-driven authorisation process, plans become vulnerable to inappropriate utilisation, over-prescribing, and non-medical consumption – all of which lead to rapid, unsustainable cost inflation.
The Global Picture: Utilization and Spend are Rising at Extraordinary Speed
Multiple health systems and insurers have reported unprecedented growth in GLP-1 prescribing:
Spending grew almost 600% in just five years. According to the American Medical Association (AMA), US spending on GLP-1 drugs grew from US$3.1 billion in 2019 to US$27 billion in 2022 – an almost nine-fold increase – driven largely by off-label use for weight loss.
50 million global users by 2030. UBS analysts project worldwide GLP-1 utilisation to exceed 50 million people by 2030, describing GLP-1s as a “structural demand story” with no signs of slowing.
Prices remain high. Even in 2025, Wegovy and Ozempic typically cost US$800-1,400 per month in many private markets. Mounjaro can be even more costly. For employer plans, a single member using GLP-1 therapy can add thousands of dollars per year to claims costs.
Employers are seeing impact on loss ratios. Major international insurers report that GLP-1 claims are now one of the top outpatient cost drivers, particularly on plans with rich benefit schedules.
In short: demand is surging, costs are high, and even a small increase in utilization can materially distort a company’s loss ratio.
WHO’s First Guidance: a Significant Milestone
In December 2025, the World Health Organization issued its first-ever guidance on GLP-1 medications for obesity – a major moment in global clinical policymaking.
The WHO review concluded:
- GLP-1 medications are clinically effective for weight reduction and metabolic improvement.
- They should be used only in patients who meet diagnostic criteria for obesity or overweight with comorbidities.
- Prescription should be part of a structured weight-management plan, not a standalone or lifestyle medication.
- Long-term safety monitoring is essential.
Source: WHO guidelines
This reinforces the need for employers and insurers to ensure that GLP-1 utilization aligns with recognised medical criteria – not social demand, cosmetic goals, or convenience-based prescribing.
Why This Matters for Group Health Insurance in 2026
A small number of users can distort claims. If just 3–5% of covered members use GLP-1 drugs, they can represent 15–25% of outpatient costs. This is materially unsustainable without an active management framework.
Without strict pre-authorisation, misuse is inevitable. In markets across the world, insurers have already observed:
- Prescriptions without documented BMI or comorbidities.
- Repeat prescriptions without clinical follow-up.
- Off-label prescribing for minor weight loss.
- Members sourcing medications for family members not on the plan.
Without a robust pre-authorization process, these behaviours can multiply quickly – especially when members realize the drugs are covered.
GLP-1 growth outpaces most employers’ cost containment mechanisms. Most companies have strong frameworks for high-cost inpatient claims, but few have equivalent controls for chronic outpatient medication categories. GLP-1s expose this gap.
Insurers alone may not act fast enough. Even well-resourced insurers struggle to manually review every GLP-1 request.
Brokers play a critical role in:
- Ensuring appropriate clinical criteria.
- Challenging excessive approvals.
- Modelling financial impact.
- Providing education for HR and employees.
- Negotiating sustainable plan parameters.
This is exactly where employer–insurer–broker alignment becomes essential.
What Employers Should Do Now: a 2026 GLP-1 Cost Containment Strategy
Require documented medical criteria for every pre-authorisation
At a minimum:
- BMI ≥30, or
- BMI ≥27 with comorbidity (diabetes, hypertension, dyslipidaemia, sleep apnea, etc.)
Pre-authorization should include:
- Baseline clinical assessment.
- Weight and BMI measurement.
- Treatment plan outlining lifestyle components.
- Expected duration of therapy.
This is fully aligned with WHO guidance.
Introduce evidence-based limits that protect appropriate access
One World Cover typically recommends:
- 12-week initial approval.
- Continuation only if medically appropriate progress is documented.
- Mandatory re-authorization at defined intervals.
These limits reduce misuse but ensure that eligible members continue to receive treatment.
Conduct a claims impact analysis (a good broker can model this for you)
This should include:
- Historic GLP-1 utilization.
- Cost projection under different plan designs.
- Scenarios (e.g., unrestricted vs. clinically aligned vs. capped access)
Employers who do this early in the renewal cycle avoid surprises later.
Implement member education
Clear messaging to employees:
- Who qualifies.
- Why authorization exists.
- What documentation is required.
- Available alternatives (nutrition support, physiotherapy, coaching, etc.).
Most dissatisfaction comes from lack of clarity, not restrictions themselves.
Negotiate with the insurer early
Insurers are far more flexible when engaged early rather than in the frantic weeks before renewal. Employers should negotiate:
- Coverage criteria.
- Authorization workflows.
- Preferred pricing.
- Integration of weight-management programs.
- Access to alternative medications where clinically appropriate.
Work with a broker who can challenge inappropriate approvals
The most effective GLP-1 strategies globally share one common factor: the broker acts as a cost-containment partner, not a post-renewal administrator.
One World Cover does this by:
- Monitoring utilization data.
- Identifying outlier prescribing.
- Ensuring insurer criteria are consistently applied.
- Challenging questionable claims.
- Advising on plan adjustments for the next renewal cycle.
GLP-1 oversight is not a “set and forget” exercise – it requires active stewardship.
GLP-1 Medications are Clinically Valuable – and Here to Stay
GLP-1 medications are here to stay. They are clinically valuable and will become a long-term part of chronic disease management worldwide. But they also represent one of the most significant cost risks to employer health insurance plans heading into the 2026 renewal cycle.
Employers do not need to choose between access and affordability. They need structure, visibility, and data-driven controls.
With a clear framework – aligned to WHO guidance, backed by pre-authorization, and supported by insurer and broker oversight – companies can protect budgets, support employee wellbeing, and keep GLP-1 utilization on a sustainable path.
If you’d like help evaluating your GLP-1 exposure or designing a cost containment strategy ahead of your 2026 renewal, One World Cover would be happy to support.
READ MORE >> Are Weight Loss Medications Covered by International Private Health Insurance Plans?
To learn more please get in touch: [email protected] or click here to contact us.
